CEO Michael Creedon and chief finance officer Jon Abell of SDI Group (LSE:SDI) present their interim results and answer a range of investor questions. The event, held on 10 December 2021, is brought to you by our friends at Investor Meet Company.
About the company
SDI Group designs and manufactures scientific and technology products for use in applications including life science, healthcare, astronomy, consumer manufacturing and art conservation markets through Synoptics, the Artemis, the Opus instruments, and Astles Control systems brands. The Digital Imaging segment incorporates the Synoptics brands Syngene, Synbiosis, Synoptics Health and Fistreem, the Atik brands Atik Cameras, Opus and Quantum Scientific Imaging, and the Graticules Optics business. The Sensors & Control segment combines our Sentek, Astles Control Systems, Applied Thermal Control, Thermal Exchange, MPB Industries and Chell Instruments businesses. It operates in the UK, Europe, America, Rest of Asia, and Rest of the world segments. It derives most of its revenues from the America segment.
These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.
The Richard Hunter Interview: Ian Cowie on inflation, value stocks, and healthcare